Relationship between changes in metabolic syndrome constituent components over 12 months of treatment and cognitive performance in first-episode schizophrenia
| Autor: | Sanja Kilian, Hilmar K. Luckhoff, Lebogang Phahladira, Bonginkosi Chiliza, Laila Asmal, Frederika Scheffler, S du Plessis, Robin Emsley, M R Olivier |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Adult
Male 0301 basic medicine Psychosis medicine.medical_specialty Adolescent medicine.medical_treatment Biochemistry Young Adult 03 medical and health sciences Cellular and Molecular Neuroscience Cognition 0302 clinical medicine Weight loss Internal medicine medicine Humans Effects of sleep deprivation on cognitive performance Antipsychotic Metabolic Syndrome business.industry Working memory Body Weight medicine.disease Memory Short-Term 030104 developmental biology Schizophrenia Female Neurology (clinical) medicine.symptom Metabolic syndrome Cognition Disorders business Weight gain 030217 neurology & neurosurgery Antipsychotic Agents |
| Zdroj: | Metabolic Brain Disease. 34:469-476 |
| ISSN: | 1573-7365 0885-7490 |
| Popis: | Few studies have investigated the longitudinal effects of treatment-emergent metabolic syndrome changes on cognitive performance in first-episode psychosis. The aim of the present study was to determine the associations between changes in metabolic syndrome constituent component over 12 months of treatment and end-point cognitive performance in schizophrenia spectrum disorders. This single site-cohort study included 72 minimally treated or antipsychotic-naive first-episode patients. Cognitive performance was evaluated using the MATRICS Consensus Cognitive Battery (MCCB). Our primary objective of interest was the relationship between metabolic syndrome constituent component changes over 12 months of treatment and end-point cognitive performance. Secondary objectives included investigating whether this relationship was affected by age, sex, antipsychotic dose, treatment duration and substance use. Weight gain predicted better overall cognition (p = 0.02) at end-point, adjusting for age, sex, substance use, baseline cognitive score and BMI, modal antipsychotic dose and treatment duration. Weight loss (p = 0.04) and substance use (p = 0.01) were both associated with poorer working memory performance at end-point. Low baseline BMI showed differential effects on end-point working memory performance in substance users (unfavorable) compared to non-users (favorable) (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink